Sitagliptin Glenmark 100 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin glenmark 100 mg

glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin Glenmark 50 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin glenmark 50 mg

glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin Glenmark 25 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin glenmark 25 mg

glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin SUN Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Lonamo 100 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lonamo 100 mg

egis pharmaceuticals plc, maďarsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Lonamo 50 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lonamo 50 mg

egis pharmaceuticals plc, maďarsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

JIDINUM 100 mg filmom obalené tablety Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

jidinum 100 mg filmom obalené tablety

medochemie ltd., cyprus - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

JIDINUM 50 mg filmom obalené tablety Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

jidinum 50 mg filmom obalené tablety

medochemie ltd., cyprus - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

JIDINUM 25 mg filmom obalené tablety Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

jidinum 25 mg filmom obalené tablety

medochemie ltd., cyprus - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Sitagliptin Sandoz 100 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin sandoz 100 mg

sandoz gmbh, rakúsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)